Back

Incyte Corporation

At Incyte, our therapeutic focus is primarily oncology. Since we began our drug discovery and development activities in early 2002, we have filed Investigational New Drug (IND) applications and progressed multiple internally developed proprietary compounds into clinical development. In late 2011, we received our first US Food and Drug Administration approval for Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor.

03/09/2024
Full time
Senior Director, Head of IAI Medical Affairs, Region Europe
Incyte Corporation 1110 Morges, VD, Switzerland
This is a great position within a promising therapeutic area that includes innovative medicine in Inflammation and Autoimmunity (IAI) and more in particular in Dermatology. This is the accountable leadership position in Medical Affairs Region Europe for IAI. This person will lead the Medical Affairs IAI team in Regional Headquarters (HQ) & have dotted line responsibility for the country medical affairs leads. As head of IAI Medical Affairs Region Europe, this person will lead the strategy & all medical affairs activities. This person will lead and drive Region EU IAI medical strategy for the portfolio of products and development molecules within the Global Program Teams (GPT) as well as lead strategic approval of investigator-initiated research (IIR) programs, creation and accountability of European medical plans and medical review of Medical Affairs and promotional materials.   Responsibilities Leads European cross functional strategy at GPT...